As coronavirus cases rage in India, Merck announced that it has entered into non-exclusive voluntary licensing agreements with five manufacturers of generic drugs in that country to speed and expand ...
A new Covid-19 therapy has completed its phase two human trial and the results are promising. Molnupiravir, developed by Ridgeback Biotherapeutics LP and Merck & Co., reached its endpoint objective of ...
In the search for effective COVID-19 treatments, many drugs failed to live up to their early promise. The antiviral molnupiravir performed well in trials, reducing hospitalizations and deaths among ...
People with acute COVID-19 who took the antiviral drug molnupiravir (Lagevrio) reported modest improvements in symptoms, less time off from work or study, and less healthcare utilization at 6 months ...
A new study currently available on the Research Square* preprint server has pointed out that molnupiravir treatment increases the ratio of transition to transversion mutations in coronavirus disease ...
A drug used to treat covid-19 appears to be driving the evolution of the SARS-CoV-2 coronavirus, according to an analysis of the 15 million viruses sequenced around the world so far. The analysis ...
KENILWORTH, N.J. & MIAMI--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today provided an update on the MOVe-OUT study of ...
If you’re worried about COVID, there’s a simple way to boost protection: get vaccinated. But this doesn’t work for everyone. People with weak immune systems – perhaps because of age or a medical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results